Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2014.08.039PMID 25218667PMCID PMC4333065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

  2015cited by this paper
• Quantitative chemical shift‐encoded MRI is an accurate method to quantify hepatic steatosis

  2014cited by this paper
• Liver fat quantification using a multi‐step adaptive fitting approach with multi‐echo GRE imaging

  2014cited by this paper
• Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

  2013cited by this paper
• The global NAFLD epidemic

  2013cited by this paper
• Association between novel MRI‐estimated pancreatic fat and liver histology‐determined steatosis and fibrosis in non‐alcoholic fatty liver disease

  2013cited by this paper
• Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.

  2013cited by this paper
• Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls

  2013cited by this paper
• Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

  2013cited by this paper
• Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

  2012cited by this paper
• Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial

  2012cited by this paper
• Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding

  2012cited by this paper
• Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

  2012cited by this paper
• Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis

  2012cited by this paper
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

  2011cited by this paper
• Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy

  2011cited by this paper
• Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

  2011cited by this paper
• The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

  2011cited by this paper
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011cited by this paper
• Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction.

  2011cited by this paper
• T1 independent, T2* corrected chemical shift based fat–water separation with multi‐peak fat spectral modeling is an accurate and precise measure of hepatic steatosis

  2011cited by this paper
• Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes

  2010cited by this paper
• Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Epidemiology of Non-Alcoholic Fatty Liver Disease

  2010cited by this paper
• Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease.

  2009cited by this paper
• Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

  2009cited by this paper
• Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss

  2009cited by this paper
• T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: Validation in a fat‐water‐SPIO phantom

  2009cited by this paper
• Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

  2009cited by this paper
• Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials.

  2008cited by this paper
• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  2008cited by this paper
• Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

  2008cited by this paper
• Fat quantification with IDEAL gradient echo imaging: Correction of bias from T1 and noise

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women

  2007cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality

  2005cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy

  2000cited by this paper

• Imaging Biomarkers in Metabolic Dysfunction Associated Steatotic Liver Disease

  2025cites this paper
• Doppi e tripli agonisti recettoriali nel trattamento del diabete mellito tipo 2

  2025cites this paper
• Five days of physical inactivity induced by dry immersion alter skeletal muscle metabolism and whole-body glucose tolerance in healthy men.

  2025cites this paper
• The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease

  2025cites this paper
• Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD

  2025cites this paper
• The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment

  2025cites this paper
• Ketogenic diet ameliorates MASLD via balancing mitochondrial dynamics and improving mitochondrial dysfunction

  2025cites this paper
• Effects of a gluten-free diet on weight reduction in Iranian non-celiac, non-gluten sensitive adult women undergoing an 8-week exercise program: a pilot study

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome

  2025cites this paper
• An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

  2025cites this paper
• Real-World Lifestyle Interventions are a Practical Model to Improve Liver Stiffness.

  2025cites this paper
• Excessive Intrapancreatic Fat Deposition and Risk of Pancreatic Diseases: Longitudinal Cohort Evidence from a Systematic Review with Population-Attributable Fraction Analysis.

  2025cites this paper
• Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients.

  2024cites this paper
• Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

  2024cites this paper
• Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials

  2024cites this paper
• GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients

  2024cites this paper
• Association between weight change, waist circumference change, and the risk of nonalcoholic fatty liver disease in individuals with metabolically healthy overweight or obesity and metabolically unhealthy overweight or obesity.

  2024cites this paper
• Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study

  2024cites this paper
• Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice

  2024cites this paper
• 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes

  2024cites this paper
• Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction.

  2024cites this paper
• Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis

  2024cites this paper
• Characterization of six clinical drugs and dietary intervention in the non-obese CDAA-HFD mouse model of MASH and progressive fibrosis.

  2024cites this paper
• Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis

  2024cites this paper
• Diabetes as a risk factor for MASH progression.

  2024cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: A Bidirectional Relationship with Clinical and Therapeutic Implications

  2024cites this paper
• Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.

  2024cites this paper
• Application and research progress of magnetic resonance proton density fat fraction in metabolic dysfunction-associated steatotic liver disease: a comprehensive review

  2024cites this paper
• Noninvasive Tests in Assessment of Patients with Alcohol-Associated Liver Disease.

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review

  2024cites this paper
• Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

  2024cites this paper
• Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology.

  2023cites this paper
• Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists

  2023cites this paper
• Impact of Nonalcoholic Fatty Liver Disease (NAFLD) on Weight Loss After Bariatric Surgery

  2023cites this paper
• Steatosis Quantification on Ultrasound Images by a Deep Learning Algorithm on Patients Undergoing Weight Changes

  2023cites this paper
• The Effect of Lifestyle Modification on the Recovery of Non-Alcoholic Fatty Liver Disease in Health Insurance Staff in Tabriz, Iran: A Randomized Clinical Trial

  2023cites this paper
• Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.

  2023cites this paper
• Effects of Cornus mas L. on anthropometric and biochemical parameters among metabolic associated fatty liver disease patients: Randomized clinical trial.

  2023cites this paper
• S3-Leitlinie Klinische Ernährung in der Chirurgie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) e. V.

  2023cites this paper
• Review of paediatric obesity and non‐alcoholic fatty liver disease—A focus on emerging non‐pharmacologic treatment strategies

  2023cites this paper
• Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis

  2023cites this paper
• Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases

  2023cites this paper
• Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes

  2023cites this paper
• Abdominal magnetic resonance imaging assessment and quantification of pancreatic and liver adipose tissues in obesity before and after laparoscopic sleeve gastrectomy

  2023cites this paper
• How far are we from an approved drug for nonalcoholic steatohepatitis?

  2023cites this paper
• Stéatose hépatique non alcoolique : diagnostic et traitement en 2022

  2023cites this paper
• Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III

  2023cites this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cites this paper
• Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis.

  2023cites this paper
• Pathophysiology of obesity and its associated diseases

  2023cites this paper
• Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD

  2023cites this paper
• Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition

  2022cites this paper
• Impact of Cotadutide Drug on Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

  2022cites this paper
• Hepatoprotective Effects of Ixeris chinensis on Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice: An Integrated Gut Microbiota and Metabolomic Analysis

  2022cites this paper
• Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

  2022cites this paper
• Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double‐blind clinical trial

  2022cites this paper
• Interaction between increasing body mass index and spinal cord injury to the probability of developing a diagnosis of nonalcoholic fatty liver disease

  2022cites this paper
• Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis

  2022cites this paper
• Berberine in Non-Alcoholic Fatty Liver Disease—A Review

  2022cites this paper
• Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study

  2022cites this paper
• Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD

  2021cites this paper
• Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium‐glucose cotransporter 2 inhibitors: a retrospective study

  2021cites this paper
• Variation in Lifestyle-Related Behavior Among Obese Indian Patients With Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity

  2021cites this paper
• Effectiveness and safety of Shugan Jianpi (SGJP) formula in the treatment of nonalcoholic steatohepatitis (NASH)

  2021influential citation
• Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction

  2021cites this paper
• Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician’s Guide

  2021cites this paper
• Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis

  2021cites this paper
• Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis.

  2021cites this paper
• Omega 3‐rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo‐controlled clinical trial

  2021cites this paper
• Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial.

  2021cites this paper
• A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease

  2021influential citation
• Liver Fat Reduction After Gastric Banding and Associations with Changes in Insulin Sensitivity and β‐Cell Function

  2021cites this paper
• Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)

  2021cites this paper
• Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies

  2020cites this paper
• Role of Magnetic Resonance Imaging in the Monitoring of Patients with Nonalcoholic Fatty Liver Disease: Comparison with Ultrasonography, Lipid Profile, and Body Mass Index.

  2020cites this paper
• Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH

  2020cites this paper
• Flaxseed oil in the context of a weight loss programme ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomised double-blind controlled trial

  2020cites this paper
• Nutrition and Nonalcoholic Fatty Liver Disease: Current Perspectives.

  2020cites this paper
• Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• MR Based-Imaging Biomarkers in NAFLD/NASH

  2020cites this paper
• MRI estimated changes in visceral adipose tissue and liver fat fraction in patients with obesity during a very low-calorie-ketogenic diet compared to a standard low-calorie diet.

  2020cites this paper
• Nonalcoholic Steatohepatitis: A Review.

  2020cites this paper
• Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases

  2020cites this paper
• Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C)

  2020cites this paper
• Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  2020cites this paper
• Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?

  2020cites this paper
• NAFLD as a continuum: from obesity to metabolic syndrome and diabetes

  2020cites this paper
• Effects of obesity reduction on transient elastography-based parameters in pediatric non-alcoholic fatty liver disease.

  2020cites this paper
• Weight Gain during Early Adulthood, Trajectory of Body Shape and the Risk of Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study among Women.

  2020cites this paper
• Clusterin overexpression protects against western diet-induced obesity and NAFLD

  2020cites this paper
• Resistance Exercise Regulates Hepatic Lipolytic Factors as Effective as Aerobic Exercise in Obese Mice

  2020cites this paper
• Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)

  2020cites this paper
• Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials

  2020cites this paper
• Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD

  2020cites this paper
• Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

  2020cites this paper
• Both Aerobic and Resistance Exercise Ameliorate Nonalcoholic Fatty Liver Disease Even in the Absence of Weight Reduction in High-fat Diet-induced Obese Mice

  2020cites this paper
• Quantification of Human Central Adipose Tissue Depots: An Anatomically Matched Comparison Between DXA and MRI

  2019cites this paper
• Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis – Clinical Translatability and Applicability in Preclinical Drug Development

  2019cites this paper
• Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders

  2019cites this paper